作者
Milind M Javle, Karthikeyan Murugesan, Rachna T Shroff, Mitesh J Borad, Reham Abdel-Wahab, Alexa Betzig Schrock, Jon Chung, Lipika Goyal, Garrett M Frampton, Robin Kate Kelley, Vincent A Miller, Jeffrey S Ross, Tanios S Bekaii-Saab, Siraj Mahamed Ali, Lee A Albacker
发表日期
2019/5/20
来源
Journal of Clinical Oncology
卷号
37
期号
15_suppl
页码范围
4087-4087
出版商
American Society of Clinical Oncology
简介
4087
Background: The management of CCA has evolved as targeted and immune checkpoint inhibitor (ICPI) therapies have emerged. We used comprehensive genomic profiling (CGP) to characterize the genomic alterations (GA) that have potential to personalize therapy for CCA. Methods: 3634 CCA underwent hybrid capture based CGP on 0.8-1.1 Mb of the coding genome to identify GAs in exons and select introns in up to 404 genes, TMB, microsatellite status (MSI) and % monoallelic genome (gLOH). PD-L1 expression was determined by IHC (Dako 22C3). Results: 52% of CCA were female with a median age of 62 years (range 16 - > 89). The most common biopsy sites were liver (74%), lymph node (4%), bile duct (3.3%), and lung (2%). MSI-high was rare (1%), 118 and 47 cases had TMB > 10 and > 20 mut/mb respectively. Of the latter, 51% (24/47) were MSI-H. PD-L1 amplification (AMP) was present in 0.27 …
学术搜索中的文章
MM Javle, K Murugesan, RT Shroff, MJ Borad… - 2019